• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

未杀死肿瘤的物质可能使其更强:化疗耐药性的计算洞察。

What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.

机构信息

Department of Mathematics, College of Science, Swansea University, Swansea SA2 8PP, United Kingdom; Computational Foundry, Swansea University, Swansea SA2 8PP, United Kingdom.

Zienkiewicz Centre for Computational Engineering, Swansea University, Swansea SA1 8EN, United Kingdom.

出版信息

J Theor Biol. 2018 Oct 7;454:253-267. doi: 10.1016/j.jtbi.2018.06.014. Epub 2018 Jun 15.

DOI:10.1016/j.jtbi.2018.06.014
PMID:29909142
Abstract

Tumour recurrence post chemotherapy is an established clinical problem and many cancer types are often observed to be increasingly drug resistant subsequent to chemotherapy treatments. Drug resistance in cancer is a multipart phenomenon which can be derived from several origins and in many cases it has been observed that cancer cells have the ability to possess, acquire and communicate drug resistant traits. Here, an in silico framework is developed in order to study drug resistance and drug response in cancer cell populations exhibiting various drug resistant features. The framework is based on an on-lattice hybrid multiscale mathematical model and is equipped to simulate multiple mechanisms on different scales that contribute towards chemotherapeutic drug resistance in cancer. This study demonstrates how drug resistant tumour features may depend on the interplay amongst intracellular, extracelluar and intercellular factors. On a cellular level, drug resistant cell phenotypes are here derived from inheritance or mutations that are spontaneous, drug-induced or communicated via exosomes. Furthermore intratumoural heterogeneity and spatio-temporal drug dynamics heavily influences drug delivery and the development of drug resistant cancer cell subpopulations. Chemotherapy treatment strategies are here optimised for various in silico tumour scenarios and treatment objectives. We demonstrate that optimal chemotherapy treatment strategies drastically depend on which drug resistant mechanisms are activated, and that furthermore suboptimal chemotherapy administration may promote drug resistance.

摘要

化疗后肿瘤复发是一个既定的临床问题,许多癌症类型在化疗后往往表现出越来越强的耐药性。癌症的耐药性是一种多方面的现象,它可以源自多个来源,在许多情况下,已经观察到癌细胞具有拥有、获得和传播耐药性特征的能力。在这里,开发了一种计算框架,以便研究表现出各种耐药特征的癌细胞群体中的耐药性和药物反应。该框架基于网格混合多尺度数学模型,能够模拟对癌症的化疗耐药性有贡献的不同尺度上的多种机制。本研究表明,耐药性肿瘤特征可能取决于细胞内、细胞外和细胞间因素之间的相互作用。在细胞水平上,耐药细胞表型源自自发的、药物诱导的或通过外泌体传递的遗传或突变。此外,肿瘤内异质性和时空药物动力学严重影响药物输送和耐药性癌细胞亚群的发展。在这里,针对各种虚拟肿瘤情况和治疗目标优化了化疗治疗策略。我们证明,最佳化疗治疗策略在很大程度上取决于哪些耐药机制被激活,而且,次优的化疗给药可能会促进耐药性。

相似文献

1
What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.未杀死肿瘤的物质可能使其更强:化疗耐药性的计算洞察。
J Theor Biol. 2018 Oct 7;454:253-267. doi: 10.1016/j.jtbi.2018.06.014. Epub 2018 Jun 15.
2
Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model.建立细胞周期异质性对实体瘤化疗反应影响的模型:来自混合多尺度细胞自动机模型的生物学见解。
J Theor Biol. 2012 Sep 7;308:1-19. doi: 10.1016/j.jtbi.2012.05.015. Epub 2012 May 29.
3
Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.模拟肿瘤生长过程中化疗诱导的耐药性状选择。
J Theor Biol. 2018 Jan 7;436:120-134. doi: 10.1016/j.jtbi.2017.10.005. Epub 2017 Oct 13.
4
Adaptive therapy.适应性疗法
Cancer Res. 2009 Jun 1;69(11):4894-903. doi: 10.1158/0008-5472.CAN-08-3658.
5
Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.癌症中的细胞群体异质性与耐药性演变:生物学与数学评估、理论治疗优化
Biochim Biophys Acta. 2016 Nov;1860(11 Pt B):2627-45. doi: 10.1016/j.bbagen.2016.06.009. Epub 2016 Jun 20.
6
Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model.最优非交叉耐药化疗策略在 Goldie 和 Coldman 癌症模型中的应用。
Math Biosci. 2013 Oct;245(2):282-98. doi: 10.1016/j.mbs.2013.07.020. Epub 2013 Aug 6.
7
The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling.数学建模在辅助化疗方案制定方面的应用。
J Math Biol. 2004 Apr;48(4):375-422. doi: 10.1007/s00285-003-0246-2. Epub 2003 Oct 27.
8
Modelling chemotherapy resistance in palliation and failed cure.模拟姑息治疗和治愈失败中的化疗耐药性。
J Theor Biol. 2009 Mar 21;257(2):292-302. doi: 10.1016/j.jtbi.2008.12.006. Epub 2008 Dec 11.
9
Exosomes and their role in tumorigenesis and anticancer drug resistance.外泌体及其在肿瘤发生和抗癌药物耐药中的作用。
Drug Resist Updat. 2019 Jul;45:1-12. doi: 10.1016/j.drup.2019.07.003. Epub 2019 Jul 23.
10
A theoretical quantitative model for evolution of cancer chemotherapy resistance.癌症化疗耐药性演变的理论定量模型。
Biol Direct. 2010 Apr 20;5:25. doi: 10.1186/1745-6150-5-25.

引用本文的文献

1
A comprehensive review of computational cell cycle models in guiding cancer treatment strategies.计算细胞周期模型在指导癌症治疗策略中的综合综述。
NPJ Syst Biol Appl. 2024 Jul 5;10(1):71. doi: 10.1038/s41540-024-00397-7.
2
Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality.冷冻休克肿瘤细胞通过合成致死作用递送 CRISPR-Cas9 以实现肺癌消退。
Sci Adv. 2024 Mar 29;10(13):eadk8264. doi: 10.1126/sciadv.adk8264.
3
Digitize your Biology! Modeling multicellular systems through interpretable cell behavior.
将你的生物学数字化!通过可解释的细胞行为对多细胞系统进行建模。
bioRxiv. 2023 Nov 5:2023.09.17.557982. doi: 10.1101/2023.09.17.557982.
4
Emerging Progress of RNA-Based Antitumor Therapeutics.基于 RNA 的抗肿瘤治疗的新进展。
Int J Biol Sci. 2023 Jun 19;19(10):3159-3183. doi: 10.7150/ijbs.83732. eCollection 2023.
5
Nanoparticle-mediated cancer cell therapy: basic science to clinical applications.纳米颗粒介导的癌细胞治疗:从基础科学到临床应用。
Cancer Metastasis Rev. 2023 Sep;42(3):601-627. doi: 10.1007/s10555-023-10086-2. Epub 2023 Feb 24.
6
Progresses, Challenges, and Prospects of CRISPR/Cas9 Gene-Editing in Glioma Studies.CRISPR/Cas9基因编辑在胶质瘤研究中的进展、挑战与前景
Cancers (Basel). 2023 Jan 6;15(2):396. doi: 10.3390/cancers15020396.
7
Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies.吗啉取代的喹唑啉衍生物作为抗MCF-7、A549和SHSY-5Y癌细胞系的抗癌剂及作用机制研究
RSC Med Chem. 2022 Apr 5;13(5):599-609. doi: 10.1039/d2md00023g. eCollection 2022 May 25.
8
Recent Advances in Device Engineering and Computational Analysis for Characterization of Cell-Released Cancer Biomarkers.用于表征细胞释放的癌症生物标志物的设备工程与计算分析的最新进展
Cancers (Basel). 2022 Jan 7;14(2):288. doi: 10.3390/cancers14020288.
9
MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets.微小RNA与癌症药物反应/耐药中的可变mRNA剪接事件:强大的治疗靶点
Biomedicines. 2021 Dec 2;9(12):1818. doi: 10.3390/biomedicines9121818.
10
Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.使用数学模型量化响应BRAFV600E-MEK-ERK级联抑制的ERK活性。
Br J Cancer. 2021 Nov;125(11):1552-1560. doi: 10.1038/s41416-021-01565-w. Epub 2021 Oct 7.